<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Follicular dendritic cells (<z:chebi fb="17" ids="38848">FDCs</z:chebi>) support the survival of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNFalpha) is overexpressed by FL cells and is critical in the development and maintenance of <z:chebi fb="17" ids="38848">FDCs</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesised that TNFalpha might be an ideal therapeutic target </plain></SENT>
<SENT sid="3" pm="."><plain>We treated seven patients with relapsed/refractory FL with 8 weeks of etanercept, 25 mg SC on day 1 and 4 of each week </plain></SENT>
<SENT sid="4" pm="."><plain>Patients without progression received 16 additional weeks of etanercept </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients completed at least 8 weeks of etanercept and two patients completed 24 weeks </plain></SENT>
<SENT sid="6" pm="."><plain>At the 8 week evaluation five patients had SD </plain></SENT>
<SENT sid="7" pm="."><plain>Of the five with SD, two progressed at 9 and 12 weeks on therapy and the remaining three progressed between 12 and 24 weeks after initiating therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Minimal toxicity was observed </plain></SENT>
<SENT sid="9" pm="."><plain>FDG-PET imaging demonstrated decreases in standardized uptake value (SUV) following treatment with etanercept in five patients </plain></SENT>
<SENT sid="10" pm="."><plain>Further studies in FL targeting the microenvironment in conjunction with standard cytotoxic therapy are warranted </plain></SENT>
</text></document>